JP2018021046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018021046A5 JP2018021046A5 JP2017155657A JP2017155657A JP2018021046A5 JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5 JP 2017155657 A JP2017155657 A JP 2017155657A JP 2017155657 A JP2017155657 A JP 2017155657A JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- dosage form
- unit dosage
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- -1 1-naphth-2-ylethyl Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91932307P | 2007-03-20 | 2007-03-20 | |
| US60/919,323 | 2007-03-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015211991A Division JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018021046A JP2018021046A (ja) | 2018-02-08 |
| JP2018021046A5 true JP2018021046A5 (enExample) | 2018-06-14 |
| JP6448726B2 JP6448726B2 (ja) | 2019-01-09 |
Family
ID=39719168
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2017155657A Active JP6448726B2 (ja) | 2007-03-20 | 2017-08-10 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554563A Withdrawn JP2010522170A (ja) | 2007-03-20 | 2008-03-19 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2014129790A Active JP5927241B2 (ja) | 2007-03-20 | 2014-06-25 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| JP2015211991A Active JP6373818B2 (ja) | 2007-03-20 | 2015-10-28 | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US8153659B2 (enExample) |
| EP (2) | EP3101017B1 (enExample) |
| JP (4) | JP2010522170A (enExample) |
| KR (3) | KR20170093996A (enExample) |
| CN (2) | CN103641814A (enExample) |
| AR (1) | AR065810A1 (enExample) |
| AU (1) | AU2008229383B2 (enExample) |
| BR (1) | BRPI0809011A8 (enExample) |
| CA (1) | CA2681633C (enExample) |
| CL (1) | CL2008000805A1 (enExample) |
| CO (1) | CO6231033A2 (enExample) |
| CR (2) | CR11036A (enExample) |
| EC (1) | ECSP099663A (enExample) |
| ES (2) | ES2734253T3 (enExample) |
| IL (1) | IL200990A (enExample) |
| MX (1) | MX2009010082A (enExample) |
| MY (1) | MY180812A (enExample) |
| NI (1) | NI200900170A (enExample) |
| NZ (2) | NZ599199A (enExample) |
| PE (1) | PE20081894A1 (enExample) |
| RU (1) | RU2471794C2 (enExample) |
| UA (1) | UA97976C2 (enExample) |
| UY (1) | UY30977A1 (enExample) |
| WO (1) | WO2008115516A2 (enExample) |
| ZA (1) | ZA200906497B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
| NZ555886A (en) * | 2004-12-01 | 2009-12-24 | Celgene Corp | Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders |
| MX2009010082A (es) * | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
| WO2009085234A2 (en) | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| CA2781888C (en) * | 2009-12-11 | 2019-06-18 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| AU2013245487B2 (en) * | 2010-02-11 | 2016-03-10 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| PL3202460T3 (pl) * | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| AU2016203826B2 (en) * | 2010-02-11 | 2018-05-17 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| US9334256B2 (en) | 2011-06-15 | 2016-05-10 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| CN102731851B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 一种耐油橡胶 |
| CN102731850B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油耐磨橡胶 |
| CN102731853B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油橡胶 |
| US9133161B2 (en) * | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| CA3108974C (en) | 2012-08-09 | 2023-04-04 | Celgene Corporation | Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| LT2882441T (lt) | 2012-08-09 | 2020-07-27 | Celgene Corporation | Su imunitetu susijusių ir uždegiminių ligų gydymas |
| AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| NZ629456A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
| US20180078539A1 (en) | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
| US10159665B2 (en) | 2016-03-23 | 2018-12-25 | Louis Habash | Preventing amyloid plaque formation by treating a human subject with a nitroxide |
| JP2019509352A (ja) * | 2016-03-23 | 2019-04-04 | ルイス ハバシュ， | ヒトの被験物質をニトロキシドで処理することによってａｐｏｐｔｏｓｉｓ関連遺伝子の発現レベルを増加させる |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| KR102368555B1 (ko) * | 2016-12-16 | 2022-02-28 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP4467143B1 (en) | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019196812A1 (zh) * | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| FI3784663T3 (fi) | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| BR122022012697B1 (pt) * | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AU2019348094B2 (en) * | 2018-09-30 | 2022-12-22 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| IL281845B2 (en) | 2018-10-01 | 2025-06-01 | Celgene Corp | Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma |
| US20220001018A1 (en) * | 2018-11-01 | 2022-01-06 | Northwestern University | Targeting pleckstrin-2 for treating cancer |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| WO2020114482A1 (zh) | 2018-12-06 | 2020-06-11 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| US20220168217A1 (en) * | 2019-02-22 | 2022-06-02 | Elkem Silicones USA Corp. | Drug delivery silicone composition to improve active ingredient elution |
| CN111606883B (zh) | 2019-02-25 | 2023-05-09 | 上海科技大学 | 基于戊二酰亚胺骨架的含硫化合物及其应用 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| AU2021226514B2 (en) * | 2020-02-25 | 2023-10-19 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| US11787767B2 (en) * | 2020-04-17 | 2023-10-17 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor X4 and related products and methods |
| BR112023000817A2 (pt) * | 2020-07-20 | 2023-02-07 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo |
| CN116669736B (zh) * | 2021-01-05 | 2025-11-11 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| AU2023210002A1 (en) * | 2022-01-19 | 2024-08-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfur-containing isoindoline derivative |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| EP4612128A4 (en) * | 2022-11-04 | 2025-09-10 | Bristol Myers Squibb Co | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| CN116675786A (zh) * | 2023-07-10 | 2023-09-01 | 盐城师范学院 | 一种靶向传递喜树碱的环糊精超分子药物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
| TR200101502T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US7973057B2 (en) * | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| NZ555886A (en) | 2004-12-01 | 2009-12-24 | Celgene Corp | Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders |
| MY140868A (en) * | 2004-12-24 | 2010-01-29 | Astrazeneca Ab | Amide derivatives |
| MX2009010082A (es) * | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
-
2008
- 2008-03-19 MX MX2009010082A patent/MX2009010082A/es active IP Right Grant
- 2008-03-19 KR KR1020177021704A patent/KR20170093996A/ko not_active Ceased
- 2008-03-19 KR KR1020157009558A patent/KR101791757B1/ko active Active
- 2008-03-19 US US12/077,715 patent/US8153659B2/en active Active
- 2008-03-19 EP EP16170365.7A patent/EP3101017B1/en active Active
- 2008-03-19 UA UAA200910592A patent/UA97976C2/ru unknown
- 2008-03-19 ES ES16170365T patent/ES2734253T3/es active Active
- 2008-03-19 CA CA2681633A patent/CA2681633C/en active Active
- 2008-03-19 AU AU2008229383A patent/AU2008229383B2/en active Active
- 2008-03-19 CN CN201310547773.7A patent/CN103641814A/zh active Pending
- 2008-03-19 NZ NZ599199A patent/NZ599199A/xx not_active IP Right Cessation
- 2008-03-19 CN CN200880016715A patent/CN101679380A/zh active Pending
- 2008-03-19 AR ARP080101179A patent/AR065810A1/es not_active Application Discontinuation
- 2008-03-19 JP JP2009554563A patent/JP2010522170A/ja not_active Withdrawn
- 2008-03-19 ES ES08726977.5T patent/ES2601131T3/es active Active
- 2008-03-19 KR KR1020097021797A patent/KR20090121400A/ko not_active Ceased
- 2008-03-19 WO PCT/US2008/003602 patent/WO2008115516A2/en not_active Ceased
- 2008-03-19 RU RU2009138500/04A patent/RU2471794C2/ru active
- 2008-03-19 EP EP08726977.5A patent/EP2142534B1/en active Active
- 2008-03-19 BR BRPI0809011A patent/BRPI0809011A8/pt not_active Application Discontinuation
- 2008-03-19 MY MYPI20093935A patent/MY180812A/en unknown
- 2008-03-19 NZ NZ579890A patent/NZ579890A/en not_active IP Right Cessation
- 2008-03-20 CL CL2008000805A patent/CL2008000805A1/es unknown
- 2008-03-24 PE PE2008000525A patent/PE20081894A1/es not_active Application Discontinuation
- 2008-03-24 UY UY30977A patent/UY30977A1/es not_active Application Discontinuation
-
2009
- 2009-09-16 IL IL200990A patent/IL200990A/en not_active IP Right Cessation
- 2009-09-17 ZA ZA2009/06497A patent/ZA200906497B/en unknown
- 2009-09-18 NI NI200900170A patent/NI200900170A/es unknown
- 2009-09-21 CR CR11036A patent/CR11036A/es unknown
- 2009-09-30 CO CO09106869A patent/CO6231033A2/es not_active Application Discontinuation
- 2009-09-30 EC EC2009009663A patent/ECSP099663A/es unknown
-
2012
- 2012-03-01 US US13/410,216 patent/US8614328B2/en not_active Ceased
-
2013
- 2013-11-18 US US14/083,205 patent/US9181216B2/en active Active
-
2014
- 2014-06-25 JP JP2014129790A patent/JP5927241B2/ja active Active
- 2014-07-16 US US14/333,454 patent/USRE46639E1/en active Active
- 2014-08-01 CR CR20140368A patent/CR20140368A/es unknown
-
2015
- 2015-10-02 US US14/874,318 patent/US9920027B2/en active Active
- 2015-10-28 JP JP2015211991A patent/JP6373818B2/ja active Active
-
2017
- 2017-08-10 JP JP2017155657A patent/JP6448726B2/ja active Active
-
2018
- 2018-02-02 US US15/887,838 patent/US10385037B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018021046A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP2013519675A5 (enExample) | ||
| ES2656696T3 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH | |
| JP2008528514A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| JP2017504611A5 (enExample) | ||
| JP2018537507A5 (enExample) | ||
| JP2014198723A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2018529742A5 (enExample) | ||
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2020529995A5 (enExample) | ||
| JP2015537009A5 (enExample) | ||
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju |